406174-92-3

Upstream product

• 406174-94-5 (1R,2S)-6,7-Dimethoxy-1-phenyl-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid 2,6-di-tert-butyl-4-methoxy-phenyl ester 
• 406174-93-4 6,7-dimethoxy-3,4-dihydro-naphthalene-2-carboxylic acid 2,6-di-tert-butyl-4-methoxy-phenyl ester 

Downstream Products

• 406174-91-2 (1R,2R)-6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylamine 
• 406174-96-7 N-(6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-methoxymethyl-4-methyl-benzenesulfonamide 
• 406174-97-8 (6aR,12bS)-10,11-Dimethoxy-6-(toluene-4-sulfonyl)-5,6,6a,7,8,12b-hexahydro-benzo[a]phenanthridine 
• 406174-95-6 N-((1R,2R)-6,7-Dimethoxy-1-phenyl-1,2,3,4-tetrahydro-naphthalen-2-yl)-4-methyl-benzenesulfonamide 
• 174691-84-0 dihydrexidine 

Relevant academic research and scientific papers

METHOD OF ADMINISTRATION OF DOPAMINE RECEPTOR AGONISTS

Methods for treating a patient having pulmonary edema are described. The methods include administering to the lung endobronchial space of the airways of the patient an effective amount of a dopamine D1 receptor agonist. Dopamine D1 receptor agonists, including hexahydrobenzophenanthridine, hexahydrothienophenanthridine, phenylbenzodiazepine, chromenoisoquinoline, naphthoisoquinoline dopamine receptor agonists, and their pharmaceutically acceptable salts, formulated as aerosols and dry powders are also described.

The first asymmetric synthesis of a dopamine D1 agonist, dihydrexidine, employing asymmetric conjugate addition technology

The first asymmetric synthesis of benzophenanthridine dopamine D1 full agonist, dihydrexidine, was accomplished employing three key processes, external chiral ligand-controlled conjugate addition of phenyllithium, Curtius conversion of a carboxylic group